AE | Placebo group ( n = 46) | 5 mg group ( n = 47) | 10 mg group ( n = 49) | |||
---|---|---|---|---|---|---|
AEs | Treatment-related AEs b | AEs | Treatment-related AEs b | AEs | Treatment-related AEs b | |
Total incidence | 31 (67.4) | 11 (23.9) | 30 (63.8) | 12 (25.5) | 34 (69.4) | 14 (28.6) |
Nausea | 1 (2.2) | 1 (2.2) | 3 (6.4) | 2 (4.3) | 1 (2.0) | 1 (2.0) |
Pyrexia | 0 | 0 | 0 | 0 | 3 (6.1) | 0 |
Nasopharyngitis | 7 (15.2) | 0 | 4 (8.5) | 0 | 2 (4.1) | 0 |
Contusion | 4 (8.7) | 0 | 0 | 0 | 1 (2.0) | 0 |
Decreased appetite | 1 (2.2) | 1 (2.2) | 3 (6.4) | 1 (2.1) | 2 (4.1) | 2 (4.1) |
Parkinsonism | 2 (4.3) | 2 (4.3) | 2 (4.3) | 2 (4.3) | 4 (8.2) | 4 (8.2) |
Pollakiuria | 0 | 0 | 3 (6.4) | 3 (6.4) | 0 | 0 |